08:06 EDT Scholar Rock (SRRK) up 14% at $35.41 after disclosing results from EMBRAZE trial
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock Announces Positive Phase 2 Trial Results
- Scholar Rock announces results from EMBRAZE trial
- Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
- Positive Outlook on Scholar Rock’s Apitegromab Driven by Promising Trial Results and Potential in Obesity and SMA Treatment
- Promising Potential in Scholar Rock’s Obesity and SMA Programs Drives Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue